script.reportAU
Immunology

Measles mumps rubella varicella priorix tetra gsk

Brand: Priorix-Tetra®

PBAC's latest decision on Measles mumps rubella varicella priorix tetra gsk: Recommended with restriction (2007). Considered for The combination measles, mumps, rubella and varicella vaccine for children aged 12 months on the NIP.

PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
$45k/QALY
Range: $15k/QALY–$45k/QALY
Submissions
1
first 2007
Submissions
1
2007 → 2007

Eligible population

children aged 12 months on the NIP

Therapy area
Immunology
Evidence base
RCT
Key trials
Trial 038, Trial 043, Trial 044
Comparator
MMR at 12 months and MMR co-administered with VV at 18 months of age
Economic model
CUA
Open on full dashboard →